Read our COVID-19 research and news.

Webinar Technology

Spatial phenotyping of the tumor microenvironment: Implications for immunotherapy

This webinar is brought to you by the Science/AAAS Custom Publishing Office

Spatial phenotyping of the tumor microenvironment: Implications for immunotherapy

19 May 2021

11:00 a.m. ET

Register to watch recording


The patterns of tumor evolution during metastatic progression and the associated clinical outcome for a cancer patient depend on the immune contexture at the site of metastasis. Defining the immune contexture of a cancer—determined by the density, composition, functional state, and organization of the leukocyte infiltrate of the tumor—can yield information relevant to the prediction of the treatment response and the patient’s prognosis. The development of multiplex immunofluorescence (mIF) technologies enables spatial phenotyping of the tumor microenvironment (TME), which aids in defining the immune contexture through a quantitative assessment of immune phenotypes and functional orientation of immune cells, while simultaneously providing tissue context and spatial distribution within the TME.

Recent studies strongly suggest the importance of determining a patient’s Immunoscore as well as the need for a more comprehensive understanding, both spatially and functionally, of the simultaneous presence of multiple immune cell types within the TME. Immune contexture parameters, including the Immunoscore, have a prognostic, predictive, and mechanistic value. Once identified, the key immune elements should be translated into clinically feasible treatment protocols, integrating with the field of immunopathology.

In this webinar, our expert speaker will:

  • Describe how a spatial phenotyping approach has supported the development of Immunoscore to estimate the prognosis of colorectal cancer patients
  • Explain how spatial phenotyping enables researchers to assess pre-existing, intratumor adaptive immune responses for developing more effective immunotherapies, such as the use of checkpoint inhibitors
  • Offer insights into how a combination of multiple immune parameters might provide increased prognostic and/or predictive power
  • Answer questions during the live presentation.

This webinar will last for approximately 60 minutes.

Speaker bios

Jerome Galon, Ph.D.

Paris, France

Dr. Galon received his Ph.D. in immunology in 1996 and undertook his postdoctoral work at the U.S. National Institutes of Health (NIH) in Bethesda, Maryland. Since 2001, he has worked at the Cordeliers Research Center in Paris, France, where he has been the director of the INSERM Laboratory of Integrative Cancer Immunology since 2009. His work aims to provide a better understanding of the tumor microenvironment and the dynamics of the immune response in human tumors. His laboratory has identified and demonstrated the importance of the immune contexture when considering cancer treatment. He defined the Immunoscore as a new method for routine clinical assessment of prognosis of cancer patients.

Jackie Oberst, Ph.D.

Washington, DC

Dr. Oberst did her undergraduate training at the University of Maryland, College Park, and her Ph.D. in Tumor Biology at Georgetown University, Washington D.C. She combined her interests in science and writing by pursuing an M.A. in Journalism from the Philip Merrill College of Journalism at the University of Maryland, College Park. Dr. Oberst joined Science/AAAS in 2016 as the Assistant Editor for Custom Publishing. Before then she worked at Nature magazine, the Howard Hughes Medical Institute, The Endocrine Society, and the National Institutes of Mental Health.

Sponsored by

Get webinar alerts

For more information on upcoming webinars, recorded sessions and more, sign up for webinar alerts.

Sign up here